May. 28 at 8:12 PM
Agilent Technologies shares rose in midday trading after the life sciences and analytical instruments company reported fiscal second-quarter results that topped analyst expectations across key metrics and raised its full-year outlook. Revenue for the quarter ended April 30, 2026 reached
$1.83 billion, up 10% reported and 6.3% organically year over year, while non-GAAP EPS climbed 14% to
$1.49, beating both analyst estimates of
$1.41 and the high end of company guidance.
Agilent raised its full-year 2026 revenue forecast to between
$7.39 billion and
$7.49 billion and lifted adjusted EPS guidance to a range of
$6.00 to
$6.10, implying annual growth of 7% to 9%.
The strong results triggered several bullish analyst reactions. BofA Securities upgraded Agilent to Buy from Neutral with a
$145 price target, citing better-than-expected execution and continued momentum in LC and GC replacement cycles, which analysts believe remain in the early stages.
$A